{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:04:34Z","timestamp":1758845074632,"version":"3.44.0"},"reference-count":0,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/s0090-8258(22)01547-5","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T20:26:21Z","timestamp":1662755181000},"page":"S169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Pembrolizumab in pretreated advanced, metastatic cervical, vulvar, vaginal carcinoma (325)"],"prefix":"10.1016","volume":"166","author":[{"given":"Steven","family":"Holloway","sequence":"first","affiliation":[]},{"given":"David","family":"Miller","sequence":"additional","affiliation":[]},{"given":"Jayanthi","family":"Lea","sequence":"additional","affiliation":[]}],"member":"78","container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822015475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822015475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:01:28Z","timestamp":1758772888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822015475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":0,"alternative-id":["S0090825822015475"],"URL":"https:\/\/doi.org\/10.1016\/s0090-8258(22)01547-5","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab in pretreated advanced, metastatic cervical, vulvar, vaginal carcinoma (325)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0090-8258(22)01547-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}